bioAffinity Technologies (BIAF) Cash from Financing Activities (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Cash from Financing Activities for 6 consecutive years, with -$118513.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 111.48% year-over-year to -$118513.0; the TTM figure through Mar 2026 stood at $13.6 million (up 192.71% YoY), while the FY2025 annual figure was $14.7 million, up 161.82% from the prior year.
• Cash from Financing Activities declined to -$118513.0 in Q1 2026 per BIAF's latest filing, from $1.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $15.0 million in Q3 2022 and bottomed at -$563556.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $2.0 million across 5 years, with a median of $301363.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities tumbled 131.85% — and 2025, when it jumped 3412.08%.
• bioAffinity Technologies' Cash from Financing Activities stood at -$563556.0 in 2022, then jumped by 84.95% to -$84805.0 in 2023, then surged by 2488.86% to $2.0 million in 2024, then sank by 33.85% to $1.3 million in 2025, then sank by 108.84% to -$118513.0 in 2026.
• Business Quant data shows BIAF's Cash from Financing Activities at -$118513.0 in Q1 2026, $1.3 million in Q4 2025, and $9.3 million in Q3 2025.